Single-dose interventional study demonstrates transient reduction in platelet aggregation among healthy volunteers, indicating potential risks of herb-drug interactions with blood thinners.
Objective: To investigate the effects of the WNF on platelet aggregation and find a link between iDCR factors and platelet aggregation. Materials and Methods: Forty healthy volunteers with different iDCRs (Earth, Water, Wind, and Fire) received a single dose of 1,000 mg WNF. A blood sample was taken before and after the WNF administration at 3, 6, and 24 hours for analysis of platelet aggregation by aggregometry. Epinephrine, adenosine diphosphate (ADP) and collagen were used as platelet agonists. Results: The WNF affects platelet aggregation in some subjects, especially females with an Earth iDCR or Wind iDCR with hyperaggregation patterns at baseline. The result after WNF treatment revealed that the percentage of platelet aggregation significantly changed downward at 3 hours and then recovered to pre-dosing levels after 24 hours. Additionally, it also did not have any relationship to iDCR. There were no reported adverse drug events. Conclusion: WNF should be used with caution in patients with blood diseases and a close eye should be kept on herb-drug interactions such as with aspirin or other NSAIDs.
No takes yet. Share an insight, caveat, or question.
Limsuvan et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: